Skip Navigation



JAC Advance Access published online on August 17, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl335
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/4/861    most recent
dkl335v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ramírez, M.
Right arrow Articles by Martín-Mazuelos, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramírez, M.
Right arrow Articles by Martín-Mazuelos, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received May 19, 2006
Revised July 18, 2006
Accepted July 19, 2006

Breif report

Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species

M. Ramírez 1, M. C. Serrano 1, C. Castro 1, E. López 1, C. Almeida 2, A. Fernández 2, A. Romero 1, and E. Martín-Mazuelos 1 *

1 Servicio de Microbiología Clínica, Hospital Universitario de Valme, Seville 41014, Spain
2 Servicio de Bioestadística, Unidad Investigación, Hospital Universitario de Valme, Seville, Spain

* To whom correspondence should be addressed.
E. Martín-Mazuelos, E-mail: estrella.martin.sspa{at}juntadeandalucia.es


  Abstract

Objectives: To compare the Clinical Laboratory Standards Institute CLSI M44-A disc diffusion (DD) and M27-A2 broth microdilution (MD) methods for determining the susceptibility of Candida spp. to micafungin (FK463).

Patients and methods: A total of 355 clinical yeast isolates including 270 Candida albicans, 45 Candida glabrata, 24 Candida krusei, 11 Candida tropicalis and 5 Candida parapsilosis were studied. The MIC of micafungin was determined by following the CLSI M27-A2 guidelines (MD). Endpoints were defined as the lowest concentration of micafungin resulting in partial inhibition (IC50) of visual growth after 24/48 h of incubation at 35°C. Final concentrations were 0.008-4 mg/L of micafungin. DD testing was performed using a CLSI M44-A document with 2.5 µg micafungin discs. Zone diameter endpoints were read after 24/48 h of incubation at 35°C. Arbitrary breakpoints were 4 mg/L for MD and 15 mm for DD.

Results: The best correlation was observed when we read MD 48 h/DD 24 and 48 h (97%). When the reading was MD 24 h/DD 24 and 48 h the percentage of correlation was 95.2%.

Conclusions: The DD method performs well for testing the susceptibility of Candida spp. to micafungin. More studies involving more Candida strains with elevated MIC values are needed.

Keywords: susceptibility testing; antifungals; lipopeptides.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. M. Johnson
Issues in antifungal susceptibility testing
J. Antimicrob. Chemother., January 1, 2008; 61(suppl_1): i13 - i18.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.